HIV monitoring every six months is adequate for people on ART with stable viral suppression
Political leadership on finance and pace of scale-up needed to realise full potential of treatment as prevention
Reduced efavirenz dose suppresses HIV as well as standard dose
Cure research is new phase of HIV therapy, says US AIDS chief
FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB
Abacavir: new studies challenge the evidence of reduced potency when viral load is high
PrEP probably cost effective in middle-income countries, but too costly to slash HIV incidence
First generic HIV drugs could save US at least $920 million a year
Intellectual property “still a threat,” to antiretroviral access, says panel
